PROVIDENCE — EpiVax Inc. has received a $324,980 Small Business Innovation Research grant to continue development of a web-based test for people at risk of life-threatening immune responses to enzyme replacement treatments for Pompe disease, coinciding with the company’s 20th anniversary. Pompe disease is an inherited metabolic disorder caused by the deficiency of the acid alpha-glucosidase…
Want More Free?
To access 2 more articles, please log in or register for free.
Registered users get access to a limited number of free articles every month.